Skip to main content
SpringerLink
Log in

Management of hypertension in overweight and obese patients: A practical guide for clinicians

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The association between obesity and cardiovascular disease is well established, and up to 60% of overweight or obese patients have hypertension. Dietary interventions associated with modest weight loss are effective in controlling blood pressure and in reducing use of antihypertensive drug therapy in overweight and obese patients. However, long-term maintenance of weight loss is achieved only in a small proportion of patients. Orlistat and sibutramine may help to achieve and maintain weight loss but may not be sufficient to control blood pressure in overweight and obese hypertensive patients. Consequently, antihypertensive drug therapy is often necessary in addition to weight loss interventions. Few studies have investigated different antihypertensive drugs, specifically in overweight and obese patients with hypertension. Based on studies involving obese and nonobese patients, first-line treatment options include a diuretic alone or an angiotensin-converting enzyme (ACE) inhibitor alone. If monotherapy is inadequate for blood pressure control, combination therapy with diuretic and ACE inhibitor and/or combining either of these drugs with a calcium channel blocker are reasonable treatment options. Additional studies to further clarify the management of these patients are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727.

    Article  PubMed  Google Scholar 

  2. World Health Organization: Controlling the global obesity epidemic. http:/www.who.int/nut/obs.htm. Accessed March 2, 2005.

  3. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76–79.

    Article  PubMed  Google Scholar 

  4. Must A, Spadano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523–1529.

    Article  PubMed  CAS  Google Scholar 

  5. Sharma AM, Engeli S, Pischon T: New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertens Rep 2001, 3:152–156.

    PubMed  CAS  Google Scholar 

  6. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855–1867.

  7. Stevens VJ, Obarzanek E, Cook NR, et al.: Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. The Hypertension Prevention Research Group. Ann Intern Med 2001, 134:1–11. This trial clearly showed that patients who had lost weight and had maintained this weight reduction had a lower risk for developing hypertension. However, this goal is achieved by only few patients.

    PubMed  CAS  Google Scholar 

  8. National Institutes of Health, National Heart, Lung and Blood Institute, Obesity Education Initiative: Clinical Guidelines on the identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 1998.

    Google Scholar 

  9. Rippe JM, Crossley S, Ringer R: Obesity as a chronic disease: modern medical and lifestyle management. J Am Diet Assoc 1998, 98(10 Suppl:2):S9-S15.

    Article  PubMed  CAS  Google Scholar 

  10. Serdula MK, Mokdad AH, Williamson DF, et al.: Prevalence of attempting weight loss and strategies for controlling weight. JAMA 1999, 282:1353–1358.

    Article  PubMed  CAS  Google Scholar 

  11. Dansinger ML, Gleason JA, Griffith JL, et al.: Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005, 293:43–53.

    Article  PubMed  CAS  Google Scholar 

  12. Foster GD, Wyatt HR, Hill JO, et al.: A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003, 348:2082–2090.

    Article  PubMed  CAS  Google Scholar 

  13. Stern L, Iqbal N, Seshadri P, et al.: The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004, 140:778–785.

    PubMed  Google Scholar 

  14. Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al.: Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000, 8:399–402.

    Article  PubMed  CAS  Google Scholar 

  15. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. Finnish Diabetes Prevention Study Group. N Engl J Med 2001, 344:1343–1350.

    Article  PubMed  CAS  Google Scholar 

  16. Stamler R, Stamler J, Grimm R, et al.: Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial—the Hypertension Control Program. JAMA 1987, 257:1484–1491.

    Article  PubMed  CAS  Google Scholar 

  17. Whelton PK, Appel LJ, Espeland MA, et al.: Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998, 279:839–846.

    Article  PubMed  CAS  Google Scholar 

  18. Metz JA, Stern JS, Kris-Etherton P, et al.: A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000, 160:2150–2158.

    Article  PubMed  CAS  Google Scholar 

  19. Yanovski SZ, Yanovski JA: Obesity. N Engl J Med 2002, 346:591–602.

    Article  PubMed  CAS  Google Scholar 

  20. Bakris G, Calhoun D, Egan B, et al.: Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Orlistat and Resistant Hypertension Investigators. J Hypertens 2002, 20:2257–2267.

    Article  PubMed  CAS  Google Scholar 

  21. Lindgärde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000, 248:245–254.

    Article  PubMed  Google Scholar 

  22. Sharma AM, Golay A: Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002, 20:1873–1878.

    Article  PubMed  CAS  Google Scholar 

  23. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155–161.

    Article  PubMed  CAS  Google Scholar 

  24. McMahon FG, Fujioka K, Singh BN, et al.: Efficacy and safety of sibutramine in obese white and African-American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000, 160:2185–2191.

    Article  PubMed  CAS  Google Scholar 

  25. McMahon FG, Weinstein SP, Rowe E, et al.: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Sibutramine in Hypertensives Clinical Study Group. J Hum Hypertens 2002, 16:5–11.

    Article  PubMed  CAS  Google Scholar 

  26. Derosa G, Cicero AF, Murdolo G, et al.: Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005, 7:47–55.

    Article  PubMed  CAS  Google Scholar 

  27. Lloyd-Jones DM, Evans JC, Larson MG, et al.: Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594–599.

    PubMed  CAS  Google Scholar 

  28. Bramlage P, Pittrow D, Wittchen HU, et al.: Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904–910.

    Article  PubMed  Google Scholar 

  29. Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 41:1178–1179.

    Article  PubMed  CAS  Google Scholar 

  30. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.

    Article  PubMed  CAS  Google Scholar 

  31. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507–1513.

    Article  PubMed  CAS  Google Scholar 

  32. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868–873.

    Article  PubMed  CAS  Google Scholar 

  33. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.

    Article  PubMed  CAS  Google Scholar 

  34. Grassi G, Seravalle G, Dell’Oro R, et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761–1769.

    Article  PubMed  CAS  Google Scholar 

  35. Stein PP, Black HR: Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991, 14:425–448.

    Article  PubMed  CAS  Google Scholar 

  36. Ueshiba H, Miyachi Y: Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003, 35:532–536.

    Article  PubMed  CAS  Google Scholar 

  37. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415–420.

    Article  PubMed  CAS  Google Scholar 

  38. CIBIS-2 study group: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9–13.

    Article  Google Scholar 

  39. Ueshiba H, Miyachi Y: Effects of the long-acting calcium channel blockers, amlodipine, manidipine and clinidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 2004, 43:561–565.

    Article  PubMed  CAS  Google Scholar 

  40. White WB, Elliott WJ, Johnson MF, Black HR: Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. J Hum Hypertens 2001, 15:135–141.

    Article  PubMed  CAS  Google Scholar 

  41. Tarif N, Bakris GL: Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997, 12:2244–2250.

    Article  PubMed  CAS  Google Scholar 

  42. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997. This trial, which involved more than 35,000 hypertensive subjects with a mean follow up of 4.9 years, clearly showed that treatment with thiazide diuretics is at least as effective as treatment with lisinopril or amlodipine in the prevention of cardiovascular diseases.

    Article  Google Scholar 

  43. Reaven GM, Clinkingbeard C, Jeppesen J, et al.: Comparison of the hemodynamic and metabolic effects of low dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995, 8(5Pt 1):461–466.

    Article  PubMed  CAS  Google Scholar 

  44. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912.

    Article  PubMed  CAS  Google Scholar 

  45. Takahashi H, Nishikawa T, Mizutani T, Handa F: Oral clonidine premedication decreases energy expenditure in human volunteers. Can J Anaesth 1997, 44:268–272.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Joseph’s Hospital, Room F-541, 50 Charlton Avenue East, L8N 4A6, Hamilton, Ontario, Canada

    Francesco Dentali MD, Arya M. Sharma MD, FRCP(C) & James D. Douketis tMD, FRCP(C)

Authors
  1. Francesco Dentali MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arya M. Sharma MD, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James D. Douketis tMD, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dentali, F., Sharma, A.M. & Douketis, J.D. Management of hypertension in overweight and obese patients: A practical guide for clinicians. Current Science Inc 7, 330–336 (2005). https://doi.org/10.1007/s11906-005-0065-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-005-0065-5

Keywords

Search

Navigation